Cargando…
Angiotensin-Converting Enzyme (ACE) Inhibitors May Moderate COVID-19 Hyperinflammatory Response: An Observational Study with Deep Immunophenotyping
BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin-II receptor blockers (ARB), the most commonly prescribed antihypertensive medications, counter renin-angiotensin-aldosterone system (RAAS) activation via induction of angiotensin-converting enzyme 2 (ACE2) expression. Consid...
Autores principales: | Duvvuri, Venkata R., Baumgartner, Andrew, Molani, Sevda, Hernandez, Patricia V., Yuan, Dan, Roper, Ryan T., Matos, Wanessa F., Robinson, Max, Su, Yapeng, Subramanian, Naeha, Goldman, Jason D., Heath, James R., Hadlock, Jennifer J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934012/ https://www.ncbi.nlm.nih.gov/pubmed/36817759 http://dx.doi.org/10.34133/hds.0002 |
Ejemplares similares
-
Risk factors for severe COVID-19 differ by age for hospitalized adults
por: Molani, Sevda, et al.
Publicado: (2022) -
Risk factors for severe COVID-19 outcomes: a study of immune-mediated inflammatory diseases, immunomodulatory medications, and comorbidities in a large US healthcare system
por: Wei, Qi, et al.
Publicado: (2023) -
The angiotensin-converting enzyme (ACE) gene family of Anopheles gambiae
por: Burnham, Susan, et al.
Publicado: (2005) -
Angiotensin Converting Enzyme (ACE) and ACE2 Bind Integrins and ACE2 Regulates Integrin Signalling
por: Clarke, Nicola E., et al.
Publicado: (2012) -
Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome
por: Gómez, Juan, et al.
Publicado: (2020)